The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a development that raises questions about the integrity of rare-disease drug approvals, the New England Journal of Medicine retracted a pivotal clinical trial paper on Amgen's Tavneos after FDA findings of altered patient outcome data and unblinding of some researchers, according to Reuters.
The retraction follows FDA findings that patient outcome data were altered and some researchers had their blinding broken, undermining the data integrity supporting the drug's approval. Tavneos is used for a rare vascular disease, and the retraction hits Amgen's credibility in this area. Amgen stock (AMGN) closed at $358.33 on June 26, 2026, per market data.
Sign in to access this content
Sign InInvestors are now watching for potential FDA next steps, including any additional regulatory actions or a review of the drug's dossier. This episode may also weigh on market confidence in Amgen's rare-disease pipeline, though the impact may remain limited to this product. Support and resistance levels for the stock stand around $354–$362 based on recent trading data.